Patents by Inventor Gregory A. Hawkins

Gregory A. Hawkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240126832
    Abstract: A method comprises receiving a kernel used to convolve with an input tensor. For a first dimension of the kernel, a square block of values for each single dimensional vector of the kernel that includes all rotations of that single dimensional vector is generated. For each additional dimension of the kernel, group blocks of an immediately preceding dimension into sets of blocks, each set of blocks including blocks of the immediately preceding dimension that are aligned along a vector that is parallel to the axis of the dimension; and generate, for the additional dimension, one or more blocks of values, each block including all rotations of blocks within each of the sets of blocks of the immediately preceding dimension. The block of values corresponding to the last dimension in the additional dimensions of the kernel is output as the expanded kernel.
    Type: Application
    Filed: October 6, 2023
    Publication date: April 18, 2024
    Inventors: Jonathan Alexander Ross, Thomas Hawkins, Gregory Michael Thorson, Matt Boyd
  • Patent number: 11914782
    Abstract: In some implementations, a computing device can be configured to automatically turn off notifications when generating a notification would cause a disturbance or be unwanted by a user. The device can be configured with quiet hours during which notifications that would otherwise be generated by the computing device can be suppressed. In some implementations, quiet hours can be configured as a time period with a start time and an end time. In some implementations, quiet hours can be derived from application data. For example, calendar data, alarm clock data, map data, etc. can be used to determine when quiet hours should be enforced. In some implementations, the device can be configured with exceptions to quiet hour notification suppression. In some implementations, the user can identify contacts to which the quiet hours notification suppression should not be applied.
    Type: Grant
    Filed: February 10, 2023
    Date of Patent: February 27, 2024
    Assignee: Apple Inc.
    Inventors: Imran A. Chaudhri, Gregory Novick, Scott Forstall, Morgan Grainger, George R. Dicker, Tyler Hawkins
  • Publication number: 20170057121
    Abstract: A carbon/carbon part and processes for making carbon/carbon parts are provided. The process involves inserting a polyacrylonitrile preform (PAN preform) into a furnace, introducing an inert atmosphere into the furnace, and ramping up the furnace to a temperature greater than 1200° C. while maintaining the total pressure in the furnace greater 0.5 Atm. The method may convert the PAN preform into a carbon preform. The carbonization may be completed while maintaining the total pressure in the furnace greater than 0.5 Atm.
    Type: Application
    Filed: August 26, 2015
    Publication date: March 2, 2017
    Applicant: GOODRICH CORPORATION
    Inventors: Gregory Hawkins, Diane Main
  • Publication number: 20150070885
    Abstract: An LED lamp for use in two-by-two light fixtures having coplanar electrical receptacles. The LED lamp is ideal for use as a replacement of fluorescent lamps in existing fluorescent fixtures and is U shaped with electrical connectors at each end. The U shaped elongate tube is made of an outer shell defining a cavity with a PCB mounted therein. The LED elements are mounted on the PCB. The LED lamp does not have coupling connectors enabling it to emit light along the entire axial length of the tube.
    Type: Application
    Filed: September 8, 2014
    Publication date: March 12, 2015
    Inventors: Alfred Petro, Gregory Hawkins
  • Publication number: 20070185086
    Abstract: Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.1]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.
    Type: Application
    Filed: April 2, 2007
    Publication date: August 9, 2007
    Inventors: Merouane Bencherif, Craig Miller, Gregory Hawkins, Balwinder Bhatti
  • Publication number: 20060288931
    Abstract: A method of creating an air barrier on both sides of an innerliner splice on the inside surface of a green tire when a bladder release lubricant is being applied thereto to prevent contamination of the splice. High pressure air is directed through air nozzles on both sides of the innerliner splice just prior to and during the application of the lubricant. A pressure sensor detects high or low air pressure during the creation of the air barriers to stop the spray of lubricant should either situation be detected.
    Type: Application
    Filed: August 31, 2006
    Publication date: December 28, 2006
    Applicant: Bridgestone/Firestone North American Tire, LLC
    Inventors: Gregory Hawkins, Dan Shipley
  • Publication number: 20060175259
    Abstract: According to one aspect of the disclosure, there is provided an apparatus (210) for performing electrochromatography. The apparatus (210) includes a die block (222) which is movable to exert a pressure greater than atmospheric pressure on a chromatography sample plate during performance of an electrochromatography procedure. A method of performing electrochromatography is also disclosed.
    Type: Application
    Filed: June 17, 2004
    Publication date: August 10, 2006
    Inventors: David Nurok, Robert Santini, Randall Replogle, Gregory Hawkins, Henry Hawkins, James Koers
  • Publication number: 20050282823
    Abstract: Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.
    Type: Application
    Filed: October 15, 2004
    Publication date: December 22, 2005
    Applicant: TARGACEPT, INC.
    Inventors: Scott Breining, Balwinder Bhatti, Gregory Hawkins, Lan Miao, Anatoly Mazurov, Teresa Phillips, Craig Miller
  • Patent number: 6828103
    Abstract: A method of screening a subject for increased likelihood of having a favorable response to estrogen replacement therapy comprises detecting the presence of the rare form of at least one estrogen receptor alpha polymorphism in the subject, the presence of the estrogen receptor alpha polymorphism indicating the subject is more likely to have a favorable response to estrogen replacement therapy (e.g., with respect to cardiovascular health, heart disease, and/or HDL levels).
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: December 7, 2004
    Assignee: Wake Forest University
    Inventors: David M. Herrington, Timothy D. Howard, Gregory A. Hawkins, Deborah A. Meyers
  • Publication number: 20020187495
    Abstract: A method of screening a subject for increased likelihood of having a favorable response to estrogen replacement therapy comprises detecting the presence of the rare form of at least one estrogen receptor alpha polymorphism in the subject, the presence of the estrogen receptor alpha polymorphism indicating the subject is more likely to have a favorable response to estrogen replacement therapy (e.g., with respect to cardiovascular health, heart disease, and/or HDL levels).
    Type: Application
    Filed: February 22, 2002
    Publication date: December 12, 2002
    Inventors: David M. Herrington, Timothy D. Howard, Gregory A. Hawkins, Deborah A. Meyers
  • Patent number: 6048696
    Abstract: A method of analyzing a DNA molecule is disclosed. In one embodiment the method comprises the steps of exposing a DNA molecule to an effective amount of a chemical modification reagent wherein the reagent converts guanine to 8-hydroxyguanine. The oxidized product is then exposed to a DNA glycosylase enzyme and the DNA molecule is cleaved at the site of the 8-hydroxyguanine. The fragments are then resolved by electrophoresis and the position of guanine residues within the DNA molecule is determined. In a preferred embodiment of the present invention, the modification reagent is a thiazine dye and the enzyme is FPG protein.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: April 11, 2000
    Assignee: Epicentre Technologies Corporation
    Inventors: Leslie M. Hoffman, Gregory A. Hawkins
  • Patent number: 5965106
    Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 12, 1999
    Assignee: PerImmune Holdings, Inc.
    Inventors: Nicholas Pomato, Richard P. McCabe, Gregory A. Hawkins, Reinhard Bredehorst, Chong-Ho Kim, Carl-Wilhelm Vogel
  • Patent number: 5578289
    Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog.
    Type: Grant
    Filed: November 4, 1993
    Date of Patent: November 26, 1996
    Assignee: Akzo N.V.
    Inventors: Nicholas Pomato, Richard P. McCabe, Gregory A. Hawkins, Reinhard Bredehorst, Chong-Ho Kim, Carl-Wilhelm E. Vogel